BVS vs. TCMD, NPCE, GUTS, LYRA, CVRX, CERS, PLSE, ANIK, SRDX, and LUNG
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Tactile Systems Technology (TCMD), NeuroPace (NPCE), Fractyl Health (GUTS), Lyra Therapeutics (LYRA), CVRx (CVRX), Cerus (CERS), Pulse Biosciences (PLSE), Anika Therapeutics (ANIK), Surmodics (SRDX), and Pulmonx (LUNG). These companies are all part of the "surgical & medical instruments" industry.
Bioventus (NYSE:BVS) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Tactile Systems Technology has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Bioventus has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
62.9% of Bioventus shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 29.1% of Bioventus shares are held by company insiders. Comparatively, 1.0% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Tactile Systems Technology had 5 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for Tactile Systems Technology and 0 mentions for Bioventus. Tactile Systems Technology's average media sentiment score of 0.36 beat Bioventus' score of 0.00 indicating that Tactile Systems Technology is being referred to more favorably in the news media.
Tactile Systems Technology has a net margin of 10.39% compared to Bioventus' net margin of -30.49%. Tactile Systems Technology's return on equity of 17.08% beat Bioventus' return on equity.
Bioventus presently has a consensus target price of $7.67, suggesting a potential upside of 92.63%. Tactile Systems Technology has a consensus target price of $30.00, suggesting a potential upside of 109.79%. Given Tactile Systems Technology's higher probable upside, analysts plainly believe Tactile Systems Technology is more favorable than Bioventus.
Tactile Systems Technology received 334 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 69.44% of users gave Tactile Systems Technology an outperform vote while only 59.52% of users gave Bioventus an outperform vote.
Summary
Tactile Systems Technology beats Bioventus on 14 of the 17 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
